All Atrial fibrillation articles
Changes to the NICE atrial fibrillation (AF) guideline and anticoagulation treatment options—what do they mean to you?
This promotional animation has been commissioned by Bayer plc and developed in partnership with Guidelines.
View Xarelto▼ (rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-2154 December 2021
Patients with atrial fibrillation report fewer adverse renal outcomes and a slower decline in renal function on rivaroxaban compared with warfarin
This animation has been developed and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals.
432-GB-2100230 June 2021
This video has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View Xarelto▼(rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-1924 January 2021
Independent professional body guideline
Recommendations for primary care on the role of oral anticoagulant treatment in people with non-valvular atrial fibrillation.
Working party guideline/algorithm
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.
Read the latest recommendations on the management of atrial fibrillation and ventricular arrhythmias in acute coronary syndrome, coronary heart disease, and left-ventricular dysfunction as well as arrhythmias associated with cardiac arrest and coronary artery bypass graft.